Business Wire

Inversago Pharma Initiates Clinical Trials, with a Phase 1 study of INV-101, the Company’s Lead Peripheral CB1 Blocker

Share

Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has initiated a Phase 1 clinical trial of INV-101, the Company’s peripherally-acting CB1 blocker, which is being developed for the treatment of Prader-Willi syndrome (PWS) and non-alcoholic steatohepatitis (NASH).

The trial will evaluate the safety, tolerability and pharmacokinetics of INV-101. Recruitment is ongoing and will enroll healthy participants in Canada, from 18 to 55 years old. Subjects will initially be randomized to receive a single dose of placebo or one of 5 dose levels of INV-101.

“With the launch of this first-in-human trial, Inversago is now a clinical-stage company, and confirms its lead in the comeback of small molecule peripheral CB1 blockers”, said François Ravenelle, PhD, CEO and founder of Inversago Pharma.

“Dosing of our first patient with INV-101 represents an important milestone to accomplish the Company’s vision: offering a potentially meaningful therapeutic option to underserved patient populations, like in PWS and NASH" said Carlo Incerti, M.D., Chairman of the Board of Inversago. "This study is the first step in the clinical development of our peripherally-acting CB1 blockers, and we expect it to provide important information about its safety and pharmacokinetics profile", concluded Dr. Incerti.

The Company’s second program, INV-202, is presently in IND-enabling preclinical studies, while other programs are in earlier stages of development. With its current pipeline, Inversago is well positioned to fully exploit peripheral CB1 blockade for a wide range of underserved metabolic indications with differentiated products.

About INV-101

INV-101 is a first-in-class, small molecule CB1 inverse agonist / antagonist being developed by Inversago for the treatment of PWS and NASH. It is specifically designed to interact with peripheral CB1 receptors located in the gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs, thus aiming at a safe and effective therapeutic approach without the known liabilities of centrally-acting CB1 blockers. The peripheral CB1 blockade is a well-documented pathway, linked to many clinically meaningful metabolic benefits.

About Inversago Pharma

Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy. For more information, visit inversago.com.

Picture of our CEO and company logotype available for download at: inversago.com/en/media/

Contact information

François Ravenelle, PhD
CEO & Founder
Inversago Pharma inc.
info@inversago.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Octapharma announces FDA approval of updated NUWIQ® Prescribing Information to include immunogenicity data in previously untreated patients19.10.2020 18:29:00 EESTPress release

Octapharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved an updated Prescribing Information (PI) for NUWIQ®, Octapharma’s human cell line-derived recombinant factor VIII (FVIII). NUWIQ ® is approved for the prevention and treatment of bleeding in people with haemophilia A. The updated PI includes immunogenicity data from the NuProtect study in previously untreated patients (PUPs). FVIII inhibitor development is the most serious treatment complication in previously untreated patients (PUPs) with severe haemophilia A. The development of inhibitors against exogenous FVIII can reduce the effectiveness of treatment and negatively impact a patient's long-term joint health and quality of life. Minimising the risk of inhibitor development is therefore a key consideration in treatment decisions for PUPs. The updated NUWIQ® PI includes data from the NuProtect study, which was the largest prospective study of a single FVIII product in true PUPs. Patients rec

Activist Malala Yousafzai and American Football Coach Katie Sowers Among Others to Headline PMI® Virtual Experience Series19.10.2020 16:00:00 EESTPress release

Project Management Institute (PMI), the world's leading association for the project management profession, is providing professionals around the world the opportunity to join three more groundbreaking Virtual Experience Series events on 20 October 2020, 12 November 2020, and 9 December 2020. Hosted by journalist, television host, and executive producer Tamron Hall, these online events connect attendees to hear unique perspectives and lessons-learned from inspiring thought leaders and experts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005488/en/ Hear Pakistani education activist and the youngest Nobel Prize laureate, Malala Yousafzai, speak about advancing female education and enabling women’s leadership globally. (Photo: Business Wire) “By bringing these topics to light and providing them a global stage, we can embolden people to embrace change and lean in to new opportunities,” said Sunil Prashara, president and

FutureOn Secures Investment from the Bentley Acceleration Fund for Oil & Gas Digitalization19.10.2020 16:00:00 EESTPress release

FutureOn, the fast-growing Norwegian software company that works with an expanding portfolio of global energy companies, announced today that it has secured an investment from the Bentley Acceleration Fund and established a strategic partnership with US-based Bentley Systems to accelerate the digitalization of the oil and gas industry. FutureOn and Bentley Systems (Nasdaq: BSY), the infrastructure engineering software company, will combine FutureOn’s award-winning field design application (FieldAP) and its API-centric collaboration platform (FieldTwin) with Bentley’s iTwin platform to provide customers a next-generation digital twin solution capable of driving design methodologies in upstream project development for the next decade. Both FutureOn and Bentley platforms use open web standards to facilitate complex integration and customization, and the combined offerings are already being implemented in exploration and production workflows. “This is a significant milestone for FutureOn w

Bentley Systems announces Executive Appointments of Nicholas Cumins (Chief Product Officer), Katriona Lord-Levins (Chief Success Officer), and Chris Bradshaw (Chief Marketing Officer)19.10.2020 16:00:00 EESTPress release

Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, announced today, following the initial public offering of its stock on September 23, the company’s successful recruitment for three significant operating positions. All three new executives are presently in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005179/en/ Nicholas Cumins, Chief Product Officer, Bentley Systems (Photo: Business Wire) Greg Bentley said, “While Bentley Systems accomplished much throughout our 36 years of growth as a privately-held company, and I am proud of our executive talent depth, we obviously could not internally develop public company experience. The principal purpose of our IPO last month was to assure market liquidity for our colleagues, and especially executive shareholders, in advance of many anticipated retirements. In turn, for the executive opportunities accordingly created, our new h

Alexis Nasard to Join Kantar as CEO19.10.2020 14:20:00 EESTPress release

Kantar, the world’s leading data, insights and consulting company, announces the appointment of Alexis Nasard as Chief Executive Officer, effective 30 December 2020. Alexis Nasard joins Kantar with almost 30 years’ experience in the FMCG and retail world. Most recently Mr Nasard is currently CEO of Bata. Prior to that, Alexis spent six years at Heineken, culminating in the position of President of Western Europe Business and Global Chief Marketing Officer. Earlier, he worked for 17 years with Procter & Gamble, in a variety of marketing and general management roles. Mr Nasard holds an MBA degree from UC Berkeley’s Haas School of Business, USA and an MS/BS degree in Civil Engineering from Saint Joseph University, Lebanon. Of his appointment, Mr Nasard said “Throughout my career Kantar has been a trusted advisor. Kantar’s data, insights and advice informed many of the strategies, as well as communication and commercial plans my teams and I led. As much as I understand Kantar’s heritage an

Entrust Launches Next-Generation, Secure Cloud-Based Direct-to-Card ID Desktop Issuance Solution19.10.2020 14:00:00 EESTPress release

Entrust, a leading provider of trusted identities, payments and data protection, today announced the Sigma® Instant Desktop Issuance solution, an innovative direct-to-card solution for instant physical and mobile ID issuance. Designed for both cloud and on-premise deployment, the Sigma solution sets the standard for simple, secure and smart instant ID solutions across enterprise, healthcare, government, higher education and financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005238/en/ The new Entrust Sigma instant ID system leverages encryption, trusted HSM technology and secure boot to issue secure physical and mobile identities. (Photo: Business Wire) Today’s enterprises face a myriad of security challenges: From transitioning to digital operations during the pandemic, to managing the global rise in cyber-attacks, they must maintain a safe and secure flow of data − including the data stored on phy

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom